Due to its strong prognostic value, GBP2 has been incorporated into multi-gene prognostic models for several cancers, including bladder urothelial carcinoma, breast cancer, pancreatic carcinoma, ovarian cancer, primary central nervous system lymphoma, and cutaneous melanoma (88–95). This evidence concerns the gene GBP2 and cutaneous melanoma.